What Are the Challenges in Targeting MHC Class I in Cancer Therapy?
One of the main challenges in targeting MHC Class I in cancer therapy is the heterogeneity of MHC Class I expression among different tumors and even within the same tumor. Additionally, some tumors may develop further mechanisms to evade immune detection despite upregulation of MHC Class I. Overcoming these challenges requires a comprehensive understanding of the tumor microenvironment and the development of combination therapies that can effectively enhance immune responses.
